Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label extension of pimavanserin for agitation and aggression in Alzheimer's disease
2016-001128-78Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pimavanserin in Alzheimer's disease (AD), sponsored by Acadia Pharmaceuticals. Primary endpoint: Safety and tolerability of pimavanserin. Started Dec 2016; status: completed.
02
Drugs
pimavanserin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2016-001128-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001128-78.